Quantcast
Last updated on April 16, 2014 at 17:11 EDT

Latest Glycated hemoglobin Stories

2012-10-16 11:26:05

MILPITAS, Calif., Oct. 16, 2012 /PRNewswire/ -- A new study suggests that blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in type 2 diabetes patients who do not take insulin. The study is published online in Diabetes Technology & Therapeutics and appeared in the publication's September print issue. The preliminary study findings were based on a retrospective analysis of health insurance data and was led by Dr. Naunihal Virdi, Medical...

2012-10-16 04:01:55

The primary objective of this 22 week study is to investigate the change in glycosylated hemoglobin (HbA1c) after receiving the new drug, as compared to those receiving a placebo. Birmingham, AL (PRWEB) October 15, 2012 In recent years, the number of patients with type 2 diabetes has continuously been increasing worldwide. According to the information published in 2009 by the International Diabetes Federation (IDF), the number of patients with diabetes was estimated to be 285 million...

2012-10-03 10:17:22

Strategies implemented in high-income countries to improve blood glucose control in people with type 1 diabetes and so reduce complications, such as heart attacks, strokes, and early death, are working, but there is much need for further improvement, according to a study from Scotland published in this week's PLOS Medicine. Using information from national databases representing over 20 000 patients from 2005 to 2008, Scottish researchers led by Helen Colhoun from the University of Dundee,...

2012-10-03 02:28:09

HAYWARD, Calif., Oct. 3, 2012 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced the presentation of an analysis of phase 2 clinical study results for ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin Germany on Wednesday, October 3, by Dr. Robert R. Henry, MD, Chief, Section of Diabetes, Endocrinology and Metabolism at the University of California,...

2012-10-02 14:25:04

Use of electronic health records was associated with improved drug-treatment intensification, monitoring, and risk-factor control among patients with diabetes, according to a new Kaiser Permanente study. In the study, which appears in the current issue of Annals of Internal Medicine, researchers also noted greater improvements among patients with poorer control of their diabetes and lipids. The findings provide an important contribution to the evidence base by demonstrating that, for the...

2012-10-02 02:29:17

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 2, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announce data from three pooled analyses for linagliptin at the 48(th) European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin. The new analyses show linagliptin, alone or in combination with other diabetes therapies, lowered hemoglobin A1c (HbA1c or A1C) in elderly patients with type 2 diabetes, as well as in adults...

2012-10-02 02:28:43

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 2, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announce data from a pooled analysis of two phase IIb trials in adults with type 2 diabetes (T2D) for an investigational SGLT-2 inhibitor, empagliflozin, at the 48(th) European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin. The new analysis showed a reduction in systolic blood pressure with empagliflozin, which, in the...

2012-10-01 10:27:08

OAKLAND, Calif., Oct. 1, 2012 /PRNewswire/ -- Use of electronic health records was associated with improved drug-treatment intensification, monitoring and risk-factor control among patients with diabetes, according to a new Kaiser Permanente study. In the study, which appears in the current issue of Annals of Internal Medicine, researchers also noted greater improvements among patients with poorer control of their diabetes and lipids. The findings provide an important contribution...

2012-09-28 06:23:39

HAYWARD, Calif., Sept. 28, 2012 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012. The analysis was performed to facilitate selection of a dosing regimen to be further examined the...

2012-09-26 02:25:45

ALBANY, New York, September 26, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Global Diabetes Devices Market and Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share and Forecast, 2011 - 2018 [http://www.transparencymarketresearch.com/diabetes-devices-market.html ]," the global diabetes devices and drugs market was worth USD 50.8 billion in 2011 and is expected to...